中文English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

非酒精性脂肪性肝炎在研Ⅲ期临床试验新药研究进展

王钰 颜学兵

引用本文:
Citation:

非酒精性脂肪性肝炎在研Ⅲ期临床试验新药研究进展

DOI: 10.3969/j.issn.1001-5256.2022.06.037
利益冲突声明:所有作者均声明不存在利益冲突。
作者贡献声明:王钰负责资料查找与分析,撰写并修改论文;颜学兵负责选题设计,指导撰写文章并最后定稿。
详细信息
    通信作者:

    颜学兵,yxbxuzhou@126.com

Advances in phase Ⅲ drug studies on the pipeline in nonalcoholic steatohepatitis

More Information
  • 摘要: 非酒精性脂肪性肝炎(NASH)可引起肝硬化、肝癌等终末期肝病,通过治疗NASH,逆转肝脂肪变性,延缓终末期肝病的发生刻不容缓。NASH的发病机制复杂,尚无有效药物治疗,目前新药仍有巨大的市场潜力,是国内外众多制药公司竞相追逐的热点。本文主要总结了现有已进入Ⅲ期临床试验的NASH在研新药的种类、作用机制、研究现状以及未来市场前景。

     

  • [1] NEGRO F. Natural history of NASH and HCC[J]. Liver Int, 2020, 40(Suppl 1): 72-76. DOI: 10.1111/liv.14362.
    [2] CHITTURI S, WONG VW, CHAN WK, et al. The Asia-Pacific Working Party on Non-alcoholic Fatty Liver Disease guidelines 2017-Part 2: Management and special groups[J]. J Gastroenterol Hepatol, 2018, 33(1): 86-98. DOI: 10.1111/jgh.13856.
    [3] PENG C, STEWART AG, WOODMAN OL, et al. Non-alcoholic steatohepatitis: A review of its mechanism, models and medical treatments[J]. Front Pharmacol, 2020, 11: 603926. DOI: 10.3389/fphar.2020.603926.
    [4] MOTA M, BANINI BA, CAZANAVE SC, et al. Molecular mechanisms of lipotoxicity and glucotoxicity in nonalcoholic fatty liver disease[J]. Metabolism, 2016, 65(8): 1049-1061. DOI: 10.1016/j.metabol.2016.02.014.
    [5] QIAO B, ZHOU Y, MA WJ, et al. Intestinal microflora imbalance in non-alcoholic fatty liver disease[J/CD]. Chin J Liver Dis: Electronic Edition, 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005.

    乔兵, 周永, 马文洁, 等. 肠道菌群失调在非酒精性脂肪性肝病中研究进展[J/CD]. 中国肝脏病杂志(电子版), 2020, 12(4): 29-33. DOI: 10.3969/j.issn.1674-7380.2020.04.005.
    [6] BOURSIER J, MUELLER O, BARRET M, et al. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota[J]. Hepatology, 2016, 63(3): 764-775. DOI: 10.1002/hep.28356.
    [7] PAWLAK M, LEFEBVRE P, STAELS B. Molecular mechanism of PPARα action and its impact on lipid metabolism, inflammation and fibrosis in non-alcoholic fatty liver disease[J]. J Hepatol, 2015, 62(3): 720-733. DOI: 10.1016/j.jhep.2014.10.039.
    [8] GAWRIEH S, NOUREDDIN M, LOO N, et al. Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: A randomized controlled double-blind phase 2 trial[J]. Hepatology, 2021, 74(4): 1809-1824. DOI: 10.1002/hep.31843.
    [9] KRISHNAPPA M, PATIL K, PARMAR K, et al. Effect of saroglitazar 2 mg and 4 mg on glycemic control, lipid profile and cardiovascular disease risk in patients with type 2 diabetes mellitus: A 56-week, randomized, double blind, phase 3 study (PRESS XⅡ study)[J]. Cardiovasc Diabetol, 2020, 19(1): 93. DOI: 10.1186/s12933-020-01073-w.
    [10] SVEN MF, PIERRE B, MANAL FA, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: Design of the NATIVE study[J]. Contemp Clin Trials, 2020, 98: 106170. DOI: 10.1016/j.cct.2020.106170.
    [11] ZAREI M, AGUILAR-RECARTE D, PALOMER X, et al. Revealing the role of peroxisome proliferator-activated receptor β/δ in nonalcoholic fatty liver disease[J]. Metabolism, 2021, 114: 154342. DOI: 10.1016/j.metabol.2020.154342.
    [12] MCCOMMIS KS, HODGES WT, BRUNT EM, et al. Targeting the mitochondrial pyruvate carrier attenuates fibrosis in a mouse model of nonalcoholic steatohepatitis[J]. Hepatology, 2017, 65(5): 1543-1556. DOI: 10.1002/hep.29025.
    [13] COLCA JR, MCDONALD WG, ADAMS WJ. MSDC-0602K, a metabolic modulator directed at the core pathology of non-alcoholic steatohepatitis[J]. Expert Opin Investig Drugs, 2018, 27(7): 631-636. DOI: 10.1080/13543784.2018.1494153.
    [14] HARRISON SA, ALKHOURI N, DAVISON BA, et al. Insulin sensitizer MSDC-0602K in non-alcoholic steatohepatitis: A randomized, double-blind, placebo-controlled phase Ⅱb study[J]. J Hepatol, 2020, 72(4): 613-626. DOI: 10.1016/j.jhep.2019.10.023.
    [15] BHATTACHARYA D, BASTA B, MATO JM, et al. Aramchol downregulates stearoyl CoA-desaturase 1 in hepatic stellate cells to attenuate cellular fibrogenesis[J]. JHEP Rep, 2021, 3(3): 100237. DOI: 10.1016/j.jhepr.2021.100237.
    [16] FERNÁNDEZ-RAMOS D, LOPITZ-OTSOA F, DELACRUZ-VILLAR L, et al. Arachidyl amido cholanoic acid improves liver glucose and lipid homeostasis in nonalcoholic steatohepatitis via AMPK and mTOR regulation[J]. World J Gastroenterol, 2020, 26(34): 5101-5117. DOI: 10.3748/wjg.v26.i34.5101.
    [17] SAFADI R, KONIKOFF FM, MAHAMID M, et al. The fatty acid-bile acid conjugate Aramchol reduces liver fat content in patients with nonalcoholic fatty liver disease[J]. Clin Gastroenterol Hepatol, 2014, 12(12): 2085-2091. e1. DOI: 10.1016/j.cgh.2014.04.038.
    [18] ALKHOURI N. Thyromimetics as emerging therapeutic agents for nonalcoholic steatohepatitis: Rationale for the development of resmetirom (MGL-3196)[J]. Expert Opin Investig Drugs, 2020, 29(2): 99-101. DOI: 10.1080/13543784.2020.1708899.
    [19] HARRISON SA, BASHIR M, MOUSSA SE, et al. Effects of resmetirom on noninvasive endpoints in a 36-week phase 2 active treatment extension study in patients with NASH[J]. Hepatol Commun, 2021, 5(4): 573-588. DOI: 10.1002/hep4.1657.
    [20] HARRISON SA, BASHIR MR, GUY CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: A multicentre, randomised, double-blind, placebo-controlled, phase 2 trial[J]. Lancet, 2019, 394(10213): 2012-2024. DOI: 10.1016/S0140-6736(19)32517-6.
    [21] KNUDSEN LB, LAU J. The discovery and development of liraglutide and semaglutide[J]. Front Endocrinol (Lausanne), 2019, 10: 155. DOI: 10.3389/fendo.2019.00155.
    [22] GHAZANFAR H, KANDHI SD, NAWAZ I, et al. Role of glucagon-like peptide-1 receptor agonists in the management of non-alcoholic steatohepatitis: A clinical review article[J]. Cureus, 2021, 13(5): e15141. DOI: 10.7759/cureus.15141.
    [23] LEFERE S, DEVISSCHER L, TACKE F. Targeting CCR2/5 in the treatment of nonalcoholic steatohepatitis (NASH) and fibrosis: Opportunities and challenges[J]. Expert Opin Investig Drugs, 2020, 29(2): 89-92. DOI: 10.1080/13543784.2020.1718106.
    [24] KRUGER AJ, FUCHS BC, MASIA R, et al. Prolonged cenicriviroc therapy reduces hepatic fibrosis despite steatohepatitis in a diet-induced mouse model of nonalcoholic steatohepatitis[J]. Hepatol Commun, 2018, 2(5): 529-545. DOI: 10.1002/hep4.1160.
    [25] KRENKEL O, PUENGEL T, GOVAERE O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis[J]. Hepatology, 2018, 67(4): 1270-1283. DOI: 10.1002/hep.29544.
    [26] RATZIU V, SANYAL A, HARRISON SA, et al. Cenicriviroc treatment for adults with nonalcoholic steatohepatitis and fibrosis: Final analysis of the phase 2b CENTAUR study[J]. Hepatology, 2020, 72(3): 892-905. DOI: 10.1002/hep.31108.
    [27] AL ATTAR A, ANTARAMIAN A, NOUREDDIN M. Review of galectin-3 inhibitors in the treatment of nonalcoholic steatohepatitis[J]. Expert Rev Clin Pharmacol, 2021, 14(4): 457-464. DOI: 10.1080/17512433.2021.1894127.
    [28] HENDERSON NC, MACKINNON AC, FARNWORTH SL, et al. Galectin-3 regulates myofibroblast activation and hepatic fibrosis[J]. Proc Natl Acad Sci U S A, 2006, 103(13): 5060-5065. DOI: 10.1073/pnas.0511167103.
    [29] HARRISON SA, DENNIS A, FIORE MM, et al. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial[J]. PLoS One, 2018, 13(9): e0203054. DOI: 10.1371/journal.pone.0203054.
    [30] ZHU Y, LIU H, ZHANG M, et al. Fatty liver diseases, bile acids, and FXR[J]. Acta Pharm Sin B, 2016, 6(5): 409-412. DOI: 10.1016/j.apsb.2016.07.008.
    [31] YOUNOSSI ZM, RATZIU V, LOOMBA R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial[J]. Lancet, 2019, 394(10215): 2184-2196. DOI: 10.1016/S0140-6736(19)33041-7.
    [32] CARIOU B, ZAÏR Y, STAELS B, et al. Effects of the new dual PPAR α/δ agonist GFT505 on lipid and glucose homeostasis in abdominally obese patients with combined dyslipidemia or impaired glucose metabolism[J]. Diabetes Care, 2011, 34(9): 2008-2014. DOI: 10.2337/dc11-0093.
    [33] RATZIU V, HARRISON SA, FRANCQUE S, et al. Elafibranor, an agonist of the peroxisome proliferator-activated receptor-α and-δ, induces resolution of nonalcoholic steatohepatitis without fibrosis worsening[J]. Gastroenterology, 2016, 150(5): 1147-1159. e5. DOI: 10.1053/j.gastro.2016.01.038.
    [34] ClinicalTrials. gov. Phase 3 Study to Evaluate the Efficacy and Safety of Elafibranor Versus Placebo in Patients With Nonalcoholic Steatohepatitis (NASH)[EB/OL]. [2022-03-23]. https://clinicaltrials.gov/ct2/show/NCT02704403?term=RESOLVE-IT&draw=1&rank=1
    [35] XIANG M, WANG PX, WANG AB, et al. Targeting hepatic TRAF1-ASK1 signaling to improve inflammation, insulin resistance, and hepatic steatosis[J]. J Hepatol, 2016, 64(6): 1365-1377. DOI: 10.1016/j.jhep.2016.02.002.
    [36] LOOMBA R, LAWITZ E, MANTRY PS, et al. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial[J]. Hepatology, 2018, 67(2): 549-559. DOI: 10.1002/hep.29514.
    [37] HARRISON SA, WONG VW, OKANOUE T, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase Ⅲ STELLAR trials[J]. J Hepatol, 2020, 73(1): 26-39. DOI: 10.1016/j.jhep.2020.02.027.
  • 加载中
计量
  • 文章访问数:  803
  • HTML全文浏览量:  269
  • PDF下载量:  183
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-10-26
  • 录用日期:  2021-11-28
  • 出版日期:  2022-06-20
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回